Our technology
Delivering tomorrow’s technology today
Synvichor’s world-first gene expression technology harnesses the power of the immune system, along with automated PCR to set a new medical standard in differentiating between joint infection and inflammation.
Current culture is still reliant on the work of Koch, Hesse and Pasteur from the 1860’s. Typical wait times for results are slow and inconclusive more than 80% of the time.
Synvichor introduces novel genomic host response-based diagnostics.
Synvichor combines proprietary biomarkers with established PCR testing techniques to translate the signalling that occurs when patients suffer joint pain.
Synvichor’s unique interpretive algorithm rapidly differentiates between infectious and non-infectious joint inflammation with up to 95%+ precision.*
